NICE rejects pomalidomide for blood cancer

Pomalidomide, a treatment for multiple myeloma, has been rejected by the National Institute for Health and Care Excellent (NICE) in its final draft guidance. Multiple myeloma is a type of cancer that affects plasma cells, which are white blood cell found in the bone marrow. Although it is incurable, there are a number of treatment options to help slow the progress of the disease and improve quality of life. NICE recommends thalidomide for most patients as a first line treatment, and bortezomib for people who are unable to take thalidomide and also as an option after the first treatment has